Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Related Content:

OncLive TVNon-Hodgkin LymphomaCAR T-cell Therapy
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer
Dr Wander on Limitations of First- and Later-Line Therapies in HR+ Breast Cancer